CVC  Numoda Capital Innovations

     Office Locations:

The Curtis Center
601 Walnut Street, 900 East
Philadelphia, PA 19106
Phone: 215-238-8881
Fax: 215-238-9995



  • Early



  • Life Sciences & Healthcare



    Numoda Capital Innovations is the investment and financing affiliate of Numoda Corporation and the manager of a new venture fund focused on life sciences companies. The fund is designed to take advantage of the attractive returns possible in promising scientific advances in the fields of healthcare therapies and preventive treatments. A uniquely favorable feature of the fund is that Numoda Corporation manages the later phase clinical trials of companies in which the fund invests, giving investors comfort that the trials are being efficiently run and have high likelihood of success. Numoda will target investments in undercapitalized companies with histories of budget overruns and missed clinical targets; companies with upcoming PII-PIII trials that had prior identifiable conduct issues (e.g., poor patient selection, faulty logistics, data inconsistency and improper study design); companies with milestone agreements in place subject to substantial risk of trial execution; and breakthrough novel technologies that would achieve a significant value inflection with early clinical success.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Ivan Joseph Director
    Mary Schaheen Chairman of the Board of Directors
    Patrick J. Keenan Chief Counsel and Strategist


    Portfolio companies include:

        web link

      MabVax Therapeutics
        web link

      MediQuest Therapeutics
        web link

      Reata Pharmaceuticals
        web link

        web link


    Recent News: